Dr. Christopher T. Chu, MD

Dr. Chu practices at Sagis Diagnostics - Houston (Directors Row) in Houston, Texas.

Dr. Chu's NPI, 1811377286, was assigned on June 1, 2015. Dr. Chu graduated from Baylor College of Medicine in 2015. Dr. Chu holds Texas license S7026.

Dr. Chu's primary practice is Sagis Diagnostics - Houston (Directors Row), at 4131 Directors Row, Houston, TX 77092. The practice phone is (877) 697-2447.

Dr. Chu's primary practice is Sagis Diagnostics - Houston (Directors Row) in Houston, Texas. The medical group on file is Sagis Diagnostics. Dmand AI also links Dr. Chu to 8 more group practices and clinics and 7 medical groups, each named with a free account. Dr. Chu's employer is on file too: a clinical lab.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chu practices, 9 sites in all. Vendor and product names are available with a free account.

Dermatopathology is Dr. Chu's primary specialty in the NPI Registry, under taxonomy code 207ND0900X. Dr. Chu is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Chu's licenses on file in 3 states: Texas, Pennsylvania and Washington.

Dmand AI lists acute skin infection, benign or precancerous skin growths, contact dermatitis, itchy rashes, scalp rash, shingles, skin cyst and skin discoloration among the conditions Dr. Chu treats.

CMS data shows 7,203 Medicare services from Dr. Chu across 17 procedure codes in 2024, for 3,580 Medicare patients. Medicare paid $373,881 for them. Every service was in an office.

CMS counts 3,580 Medicare patients who saw Dr. Chu in 2024. The largest group is 65 to 74, with 1,674 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 1% are also on Medicaid. Their average risk score is 1.02, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Chu's median patient age at 62, with 51% women.

In 2024, Dr. Chu wrote 86 Medicare Part D claims for 35 patients. 93% of them were for generic drugs. CMS names the drug for 46 of them, across 3 drugs with 11 or more claims each, at $1,274 in total drug cost. In 2023, CMS named 50 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Chu for performance year 2024, reported as part of a group. Dr. Chu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 184 procedures of skin biopsy by Dr. Chu, more than 84% of the clinicians it reports for that procedure.

Dmand AI links 5 papers to Dr. Chu, published from 2018 to 2020. 2020 was the busiest year, with 3. The most frequent topics are Dermatitis, Allergic Contact, Dermatitis, Occupational and Patch Tests. Dr. Chu's most frequent co-authors are Klaus F. Helm, MD, James G. Marks, MD and Max D. Disse, MD.

CMS Open Payments shows 123 general payments to Dr. Chu from 24 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 94% of the total. Janssen Pharmaceuticals, Inc paid the most, $738.

Dr. Chu graduated from Baylor College of Medicine in 2015.

Dr. Chu is in network with 24 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 15. Check the plan with the practice before a visit.